Bishal Gyawali: Letter to the Editor and Author Response on the ARIEL-4 Trial

Bishal Gyawali, Associate Professor at Queen’s University, shared a post on LinkedIn:

“A letter to editor we received and our response to it, both published in the February edition of The Lancet Oncology. Please read both and decide for yourself.

Also, if you want to read more about the ARIEL-4 trial that’s being discussed here, read this.”

Title: When a Cancer Drug Shortens Life: Lessons from Ariel4

Authors: Bishal Gyawali

Read the Full article in Medscape.

Bishal Gyawali: Letter to the Editor and Author Response on the ARIEL-4 Trial

Title: Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

Authors: Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, Mikhail Dvorkin, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin Lin, Karen McLachlan, Sandra Goble, Amit M Oza

Read the Full article in The Lancet Oncology.

Bishal Gyawali: Letter to the Editor and Author Response on the ARIEL-4 Trial